Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 10/20 | 0.58 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.58 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095356 | 0.95 | SCD (0.65) | SCDDCTPP1 | |
| SCHEMBL939098 | 0.86 | SCD (0.65) | SCDDCTPP1 | |
| SCHEMBL1095915 | 0.86 | SCD (0.75) | SCDDCTPP1 | |
| SCHEMBL1096168 | 0.84 | SCD (0.62) | SCDDCTPP1 | |
| SCHEMBL1096539 | 0.83 | SCD (0.66) | SCD | |
| SCHEMBL14143699 | 0.82 | SCD (0.63) | SCDDCTPP1 | |
| SCHEMBL2429972 | 0.82 | SCD (0.60) | SCDDCTPP1 | |
| Cyclohexane SCHEMBL2467082 | 0.81 | SCD (0.61) | SCDDCTPP1DGAT1 | |
| SCHEMBL1096003 | 0.80 | SCD (0.67) | SCDDCTPP1 | |
| SCHEMBL2429706 | 0.80 | SCD (0.58) | SCDDCTPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651606-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-10-24 | — | — | EP | claimed |
| JP-4782008-B2 | — | — | 2011-09-28 | — | — | JP | claimed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | claimed |
| US-7605161-B2 | 1-Pentyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}urea; inhibitors of stearoyl-CoA desaturase; cardiovascular disease, diabetes, obesity, metabolic syndrome | XENON PHARMACEUTICALS INC. (CA) | 2009-10-20 | — | — | US | claimed |
| US-20090131447-A1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2009-05-21 | — | — | US | claimed |
| CN-101163504-A | Combination therapy | XENON PHARMACEUTICALS INC (CA) | 2008-04-16 | — | — | CN | claimed |
| JP-2007500719-A | — | — | 2007-01-18 | — | — | JP | claimed |
| US-20060199802-A1 | Pyridyl derivatives and their use as therapeutic agents | DISCOVERY PARTNERS INTERNATIONAL, INC. | 2006-09-07 | — | — | US | claimed |
| CN-1829691-A | Pyridyl derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2006-09-06 | — | — | CN | claimed |
| EP-1651606-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | claimed |
| WO-2005011656-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
| EP-1651606-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-10-24 | — | — | EP | disclosed |
| US-8153636-B2 | Pyridyl derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-04-10 | — | — | US | disclosed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | disclosed |
| EP-2316825-A1 | Pyridyl derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2011-05-04 | — | — | EP | disclosed |
| US-20060199802-A1 | Pyridyl derivatives and their use as therapeutic agents | DISCOVERY PARTNERS INTERNATIONAL, INC. | 2006-09-07 | — | — | US | disclosed |
| CN-1829691-A | Pyridyl derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2006-09-06 | — | — | CN | disclosed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | disclosed |
| EP-1651606-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005011656-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131447-A1 | COMBINATION THERAPY | SCD, SCD5, ARG1 | SCD 1/4885DCTPP1 3458/4885DGAT1 1025/4885 |
| US-20060199802-A1 | Pyridyl derivatives and their use as therapeutic agents | PYCR1, PNPO, UQCRC1 | SCD 6/4885DCTPP1 1972/4885DGAT1 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.